Skip to main content

Biodesix Using VeriStrat to Evaluate Kadmon's Tyrosine Kinase Inhibitor

NEW YORK (GenomeWeb News) – Biodesix today announced it is collaborating with biopharma Kadmon to evaluate the use of Biodesix's test for a non-small cell lung cancer study for Kadmon's reversible tyrosine kinase inhibitor.

The Phase 3 study is designed to compare Kadmon's TKI called KD019 with erlotinib in patients with stage IIIB/IV NSCLC who have progressed after first- or second-line chemotherapy. KD019 targets EGFR, HER2, VEGFR2 and 3, and SRC, and Biodesix's VeriStrat test will be used on serum samples from the study. The test will be evaluated for its effectiveness in identifying patients with better or worse outcomes following treatment with KD019, Biodesix said.

Terms of the deal were not disclosed.

Partnering with biopharmas has been a strategy of Biodesix to increase adoption of its VeriStrat, a laboratory developed test launched in 2009, and a company official said in January that it was progressing on those efforts.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.